Pegtarviliase Expected News Today : Breaking News, Live Updates & Top Stories | Vimarsana

/PRNewswire/ Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as.

United statesJim kastenmayerAeglea biotherapeuticsPiper sandlerExchange commissionJp morganEuropean medicines agencyDrug administrationPrnewswire aeglea biotherapeutics incAeglea biotherapeutics incInterim clinical dataPegtarviliase expectedFourth quarterCurrently dosing cohortClassical homocystinuriaMarketing authorization application